A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis.

The purpose of this study is to determine if AMG 108 in combination with methotrexate is safe and effective in the treatment of rheumatoid arthritis.

Inclusion Criteria:

• Subjects with active rheumatoid arthritis as diagnosed by meeting ACR classification criteria for at least 6 months.
• Must be taking MTX consecutively for >/= 12 weeks and at a stable dose of methotrexate at 15-25 mg weekly for at least 4 weeks prior to screening

Exclusion Criteria:

• Receipt of commercial or experimental biologic therapies for the treatment of inflammatory disease
• Presence of serious infection
• Class IV rheumatoid arthritis
• Prior or current history of tuberculosis infection or exposure
• Any other DMARDs other than methotrexate within 6 weeks of screening
• Pregnant or nursing
• Receipt of live vaccines within 3 months
• Felty's syndrome